

# Alen Ostoje

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1592505/publications.pdf>

Version: 2024-02-01

15  
papers

202  
citations

1163117

8  
h-index

1125743

13  
g-index

15  
all docs

15  
docs citations

15  
times ranked

415  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. <i>Future Oncology</i> , 2011, 7, 1035-1043.	2.4	41
2	Ruxolitinib for the treatment of myelofibrosis: its clinical potential. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 95.	2.0	38
3	Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. <i>Journal of Hematology and Oncology</i> , 2012, 5, 43.	17.0	29
4	Early human cytomegalovirus reactivation is associated with lower incidence of relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1450-1456.	2.4	24
5	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. <i>Blood</i> , 2021, 137, 896-907.	1.4	15
6	Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 472-476.	0.4	11
7	The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation. <i>International Journal of Hematology</i> , 2015, 102, 12-24.	1.6	10
8	Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?. <i>Croatian Medical Journal</i> , 2016, 57, 6-15.	0.7	10
9	Ruxolitinib for the treatment of myelofibrosis. <i>Drugs of Today</i> , 2011, 47, 817.	1.1	8
10	Clinical characteristics and cytokine biomarkers in patients with chronic graft-versus-host disease persisting seven or more years after diagnosis. <i>American Journal of Hematology</i> , 2020, 95, 387-394.	4.1	6
11	Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 937.e1-937.e7.	1.2	5
12	Clinical characterization and cytokine profile of fatigue in hematologic malignancy patients with chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 2934-2939.	2.4	4
13	Febrile Neutropenia Following Autologous Stem Cell Transplantation in Patients with Lymphoma. <i>Blood</i> , 2008, 112, 4379-4379.	1.4	1
14	2268. Clinical Implications of Azole-Resistant vs. Azole-Susceptible Invasive Aspergillosis in Hematological Malignancy (CLARITY): A Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S776-S776.	0.9	0
15	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) — a multicenter study. <i>Open Forum Infectious Diseases</i> , 2020, 7, S795-S796.	0.9	0